Cabinet of Ministers Regulations No. 1201 Riga 2009 October 20 (pr. No 72 20) amendment to the Cabinet on 19 July 2005, the provisions of the "rules on no 528 national agency" infektoloģij Center "public service price list" Issued in accordance with the law on budget and financial management of the ninth article 5, part 1. make Cabinet of 19 July 2005, regulations No 528 "rules for State agencies Kuma" infektoloģij Center "public service price list" (Latvian journal, 2005, 115 No; 2006, 2007 101 no; 88. no; 2008, 114 no; in 2009, 72 no) amendments and express attachment as follows: "Cabinet of Ministers on 19 July 2005, regulations No 528 national agency" infektoloģij Center "public service price list no PO box
The type of service the unit price without VAT (Ls) excluding VAT (Ls) price with VAT (Ls) (I). the public services on which the associated costs shall not be covered from the State budget of 1.
1.1 the vaccination.
vaccination against tick encephalitis for 1.1.1.
vaccination against tick encephalitis (adults) 1 vaccination 21.50 0.00 21.50 1.1.2.
vaccination against tick encephalitis (children) 1 vaccination 21.00 0.00 21.00 1.2.
vaccination against rabies vaccination 14.00 0.00 14.00 1.3 1.
vaccination against yellow fever vaccination 18.00 0.00 18.00 1 1.4.
vaccination against viral hepatitis in 1.4.1.
vaccination against viral hepatitis A (adults) 1 vaccination 22.00 0.00 22.00 1.4.2.
vaccination against viral hepatitis A (child) 1 vaccination 19.00 0.00 19.00 1.4.3.
vaccination against viral hepatitis B (growth of guš) 1 vaccination 12.00 0.00 12.00 1.4.4.
vaccination against viral hepatitis B (children) 1 vaccination 9.00 0.00 9.00 1.4.5.
vaccination against viral hepatitis A and viral hepatitis B (combined vaccine in a single dose) 1 vaccination 31.00 0.00 31.00 1.5.
vaccination against chickenpox vaccination 30.00 0.00 30.00 1 1.6.
vaccination against typhoid fever vaccination 12.00 0.00 12.00 1.7 1.
vaccination against polio, diphtheria, kind of cramps 1 vaccination 11.00 0.00 11.00 1.8.
vaccination against meningococcal infection 1 vaccination 14.00 0.00 14.00 1.9.
vaccination against pneumococcal infection 1 vaccination 15.00 0.00 15.00 1.10.
vaccination against influenza is 1.10.1.
vaccination against the flu (adults) 1 vaccination 8.00 0.00 8.00 1.10.2.
vaccination against influenza vaccination (children) 1 7.00 0.00 7.00 1.11.
vaccination against cholera vaccination 23.00 0.00 23.00 1 1.12.
vaccination against epidemic of mumps, measles, rubella vaccination 1 12.00 0.00 12.00 1.13.
international certificate of vaccination or booster vaccination against yellow fever certificate 0.60 0.13 0.73 1 1.14.
itinerant vaccination 1.14.1.
vaccinations work collective (up to 50 people) 1 sail 12.00 0.00 12.00 1.14.2.
vaccinations work collective (from 51 to 100 people) 1 sail 22.00 0.00 22.00 1.14.3.
vaccinations work collective (from 101 to 200 people) 1 sail 32.00 0.00 32.00 1.14.4.
vaccinations work collective (from 201 to 300 people) 1 sail 2 42.00 0.00 42.00.
Dentist Services ** 2.1.
a first investigation and history data collection study 4.24 0.00 4.24 1 2.2.
Repeat investigation after six months 1 study 2.12 0.00 2.12 2.3.
determination of tooth vitality one tooth 1 study 0.72 0.00 0.72 2.4.
tooth higiēnist of 1 consultation consultation 2.38 0.00 2.38 2.5.
written one treatment plan 1 plan 1.86 0.00 1.86 2.6.
x-ray evaluation of assessment 1 1.14 0.00 1.14 2.7.
hygiene instruction and motivation 1 instruction 2.38 0.00 2.38 2.8.
the tooth surface treatment with pretkaries feature 1 procedure 2.59 0.00 2.59 2.9.
the tooth remove fever throughout the soft mouth 1 procedure 3.05 0.00 3.05 2.10.
the old seals into 1 procedure 0.93 0.00 0.93 2.11.
Tartar removal and polishing (one unit of time) 1 procedure 6.73 0.00 6.73 2.12.
tooth kavitāt and karioz of the mass removal, including the temporary closure of the kavitāt 1 procedure 4.45 0.00 4.45 2.13.
tooth kavitāt creation and indirect pulp capping with calcium hydroxide (Ca (OH) 2), including the temporary closure of the kavitāt 1 procedure 6.78 0.00 6.78 2.14.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and polishing 2.14.1.
incisīv, one surface 1 procedure 8.95 0.00 8.95 2.14.2.
incisīv, two surface 1 procedure 10.35 0.00 10.35 2.14.3.
premolār, one surface 1 procedure 8.95 0.00 8.95 2.14.4.
premolār, two surface 1 procedure 10.61 0.00 10.61 2.14.5.
molar, one surface 1 procedure 8.95 0.00 8.95 2.14.6.
molar, two surface 1 procedure 12.42 0.00 12.42 2.15.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and polishing 2.15.1.
incisīv, three surface 1 procedure 13.97 0.00 13.97 2.15.2.
incisīv, four surface 19.87 0.00 19.87 2.15.3 procedure 1.
premolār, three surface 1 procedure 23.81 0.00 23.81 2.15.4.
premolār, four surface 1 procedure 28.98 0.00 28.98 2.15.5.
Clinical Crown restoration procedure 1 27.95 0.00 27.95 2.16.
in the teeth of the vital pulpekstirpācij viensakn 1 procedure 8.02 0.00 8.02 2.17.
pulpekstirpācij divsakņ of the teeth in vital 1 procedure 10.35 0.00 10.35 2.18.
pulpekstirpācij trīssakņ of the teeth in vital 1 procedure 14.90 0.00 14.90 2.19.
drug insert 1 procedure starpseanso 1.40 0.00 1.40 2.20.
root canal treatment of tooth 1 procedure viensakn 5.54 0.00 5.54 2.21.
root canal filling of teeth 1 procedure viensakn 4.35 0.00 4.35 2.22.
root canal treatment of tooth divsakņ 1 procedure 6.99 0.00 6.99 2.23.
root canal filling of divsakņ dental procedure 1 7.14 0.00 7.14 2.24.
root canal treatment of tooth trīssakņ (one to two sessions) 1 procedure 11.59 0.00 11.59 2.25.
root canal filling teeth 1 procedure trīssakņ 9.47 0.00 9.47 2.26.
root canal of tooth viensakn pārārstēšan of 1 procedure 9.52 0.00 9.52 2.27.
root canal of tooth pārārstēšan divsakņ 1 procedure 11.07 0.00 11.07 2.28.
root canal of tooth pārārstēšan trīssakņ 1 procedure 13.66 0.00 13.66 2.29.
endodontisk to open the tooth treated through Crown 1 procedure 3.62 0.00 3.62 2.30.
viensakn-tooth extraction, including wounds finish 1 procedure 4.86 0.00 4.86 2.31.
daudzsakņ tooth extraction, including wounds finish procedure 1 8.69 0.00 8.69 2.32.
redirected or thin tooth extraction procedure 1 15.78 0.00 15.78 2.33.
mucous diseases local drug treatment procedure 4.81 0.00 4.81 1 2.34.
surface anesthesia procedure 1 1.55 0.00 1.55 2.35.
infiltration anesthesia procedure 1 1.66 0.00 1.66 2.36.
District 1 anesthesia procedure 2.59 0.00 2.59 2.37.
local medication (gel) into gum Pocket 1 procedure 1.50 0.00 1.50 3.
3.1 the service services.
with treatment related services ** 3.1.1.
Insert a single patient in Ward 1 days of 8.00 0.00 8.00 3.1.2.
Insert 1 patient days of boxing 12.00 0.00 12.00 3.1.3.
detoxification of alcohol intoxication and withdrawal to the stationary blending (one day) 1 days-29.00 0.00 29.00 3.1.4.
detoxification of alcohol intoxication and withdrawal for blending Hospital (two nights) for 2 days of 51.00 0.00 51.00 3.2.
medical records copying 3.2.1.
A5 copy with copy machine for A5 page 0.04 0.01 0.05 3.2.2.
A4 copies with copy machine for A4 sheet 0.05 0.01 0.06 3.2.3.
repeating the statement preparation and after issuing a written request within one week 1 document 4.28 0.90 5.18 3.2.4.
repeating the statement preparation and service the next day after receipt of the request 1 document 6.93 1.46 8.39 3.2.5.
extract translation in a foreign language (English, Russian) 1 document 5.78 1.21 6.99 3.2.6.
inability to duplicate issue 1 page document 1.00 0.21 1.21 4.
Methodically consultative work 4.1.
laboratory specialist training (with the exception of the epidemiological surveillance laboratory professionals) 1 academic hour 6.38 1.34 7.72 4.2.
training of laboratory methods 1 participant 6.38 1.34 7.72 4.3.
a thematic workshop on laboratory diagnosis (of each member) 1 member 9.60 2.02 11.62 4.4.
Lecture on diagnosis (from each participant) participant 3.17 0.67 3.84 1 4.5.
training vakcinoloģij infektoloģij Centre of Latvia in the vaccination room (from each participant) participant 12.76 2.68 15.44 1 4.6.
methodically advisory work in the prevention of infectious diseases issues 1 study 12.76 2.68 15.44 5.
Ophthalmology 5.1.
okulist inspection and spectacle out 1 study 3.50 0.00 3.50 5.2.
eye pressure measurement procedure 1 0.50 0.00 0.50 5.3.
retinoskopij for adults and children at 8 years of age 1 1.04 0.00 1.04 5.4 procedure.
retinoskopij for children up to 8 years of age 1 procedure 1.54 0.00 1.54 5.5.

oftalmometrij (keratometrij) 1 procedure 0.40 0.00 0.40 5.6.
determination of Visual acuity in children up to 8 years of age 1 procedure 0.80 0.00 0.80 5.7.
determination of Visual acuity with correction for children up to 8 years of age 1 procedure 0.80 0.00 0.80 5.8.
determination of Visual acuity for adults and children at 8 years of age 1 procedure 0.66 0.00 0.66 5.9.
determination of Visual acuity with correction for adults and children at 8 years of age 1 procedure 0.66 0.00 0.66 5.10.
tear the withdrawal quantity and/or break time (break-up time) detection 1 procedure 0.93 0.00 0.93 5.11.
autorefraktometrij procedure 1 2.19 0.00 2.19 5.12.
contact the application of the adjustment procedure 1 1.37 0.00 1.37 5.13.
contact lens wear training 1 procedure 1.72 0.00 1.72 5.14.
see the nature of the determination by 4 point color test procedure 1 0.46 0.00 0.46 5.15.
stereoredz check (Lang, TNC and "flies" tests) 1 procedure 0.72 0.00 0.72 5.16.
the upper eyelid is cut to one eye 1 procedure 0.35 0.00 0.35 5.17.
eyes massage one eye 1 procedure 0.70 0.00 0.70 5.18.
color vision test with the help of the color table 1 procedure 0.35 0.00 0.35 5.19.
the eye of biomikroskopij both eyes 1 procedure 1.31 0.00 1.31 5.20.
gonioskopij of both eyes, the result of the evaluation procedure 1 1.62 0.00 1.62 5.21.
biomikrooftalmoskopij of both eyes, the result of the evaluation procedure 1 1.94 0.00 1.94 5.22.
oftalmoskopij (direct) in both eyes, the result of the evaluation procedure 1 0.81 0.00 0.81 5.23.
oftalmoskopij (indirect) in both eyes, the result of the evaluation procedure 1 0.71 0.00 0.71 5.24.
binocular indirect oftalmoskopij, graphical display of results 1 procedure 1.84 0.00 1.84 5.25.
corneal fluorescīn of painting with both eyes 1 procedure 0.61 0.00 0.61 13.33.
removal of foreign bodies from the eye conjunctival sack or mechanical Eyelash hair removal procedure 1 0.87 0.00 0.87 5.27.
removal of foreign bodies of the cornea 2.73 0.00 2.73 5.28 procedure 1.
tear ducts of rinsing one side 1 procedure 1.94 0.00 1.94 6.
Physical medicine 6.1.
galvanising procedures 2.12 0.00 2.12 1 6.2.
medicine electrophoresis procedure 1 2.69 0.00 2.69 6.3.
are modulated sinusoidal current (SMS) 1 procedure 2.12 0.00 2.12 6.4.
are modulated sinusoidal current (SMS) forēz 1 procedure 2.90 0.00 2.90 6.5.
cavities electrophoresis procedure 2.59 0.00 2.59 1 6.6.
darsonvalizācij procedure 1 1.85 0.00 1.85 6.7.
ultraīsviļņ therapy 1 procedure 1.48 0.00 1.48 6.8.
viļņterapij inches (monoplane) procedure 1 1.42 0.00 1.42 6.9.
inch viļņterapij (biplane) 1 procedure 1.66 0.00 1.66 6.10.
decimetre viļņterapij (monoplane) 1 procedure 1.45 0.00 1.45 6.11.
decimetre viļņterapij (biplane) 1 procedure 1.66 0.00 1.66 6.12.
ultrasound therapy 1 procedure 3.31 0.00 3.31 6.13.
fonoforēz procedure 1 3.83 0.00 3.83 6.14.
a changing magnetic field therapy 1 procedure 1.40 0.00 1.40 6.15.
ultraviolet irradiation of 1 procedure 2.12 0.00 2.12 6.16.
solarium (face) 10 min * session * 1 0.93 0.20 1.13 6.17.
solarium (face) 20 min * session * 1 1.19 0.25 1.44 6.18.
solarium (face) 30 min * session * 1 1.40 0.29 1.69 6.19.
inhalation 1 session 2.59 0.00 2.59 6.20.
massage with massage apparatus 10 min 1 session 0.67 0.00 0.67 6.21.
massage with the massage machine 20 min session 1 1.40 0.00 1.40 6.22.
massage with massage apparatus 30 min session 1 1.76 0.00 1.76 6.23.
paraffin-ozokerite therapy 1 procedure 4.14 0.00 4.14 6.24.
laser therapy session 2.25 0.00 2.25 6.25 20 min 1.
laser therapy session 1 2.90 0.00 2.90 6.26 30 min.
kriodestrukcij session 1 2.28 0.00 2.28 6.27.
laser therapy 5 min 1 session 0.70 0.00 0.70 6.28.
laser therapy session for 10 minutes 1 1.04 0.00 1.04 6.29.
amplipulsterapij procedure 1 1.20 0.00 1.20 at 6.30.
low frequency magnetoterapij 1 procedure 0.82 0.00 0.82 6.31.
magnetolāzer therapy 1 procedure 1.90 0.00 1.90 6.32.
Ultrasonic spray 1 procedure 1.00 0.00 1.00 6.33.
head massage 1 procedure 1.50 0.00 1.50 6.34.
the collar zone massage 1 procedure 4.50 0.00 4.50 6.35.
arm and shoulder area massage 1 procedure 5.50 0.00 5.50 6.36.
chest massage 1 procedure 3.50 0.00 3.50 6.37.
back massage (C2-S5) 1 procedure 6.00 0.00 6.00 6.38.
abdominal massage 1 procedure 1.50 0.00 1.50 6.39.
back-cross part 1 procedure of massage 2.00 0.00 2.00 6.40.
back of neck-chest massage part 1 procedure 4.00 0.00 4.00 6.41.
back breast massage part 1 procedure 2.50 0.00 2.50 6.42.
leg and hip area massage 1 procedure 3.00 0.00 3.00 6.43.
General massage (kids, babies) 2.50 0.00 2.50 6.44 procedure 1.
General massage (1-3 years old children) 1 procedure 3.00 0.00 3.00 45.
General massage (7-14 years old children) 1 4.50 0.00 4.50 procedure 7.
Physiotherapy 7.1.
activation of the patient after the surgical diseases (30 min), 1 procedure 3.15 0.00 3.15 7.2.
pulmonoloģisk patient physiotherapy individually (50 min) 1 procedure 3.15 0.00 3.15 7.3.
postural drainage, massage, breathing exercises dynamically to individual (60 min) 1 procedure 4.00 0.00 4.00 7.4.
the patient first and functional status determination, rehabilitation programmes dialling procedure 1 4.76 0.00 4.76 7.5.
the patient was as necessary, but no less than 10 days, and finally treatment course 1 procedure 2.00 0.00 2.00 7.6.
the patient's functional investigation, carried out by a physiotherapist 1 procedure 3.56 0.00 3.56 7.7.
kinezoterapij patients with the support-system of movement or diseases of the nervous system (45 min) 1 procedure 4.00 0.00 4.00 7.8.
kinezoterapij patients with the support-system of movement or diseases of the nervous system (2 to 5 people in a group of 50 min) 1 2.00 0.00 2.00 procedure 8.
Other manipulation and procedures 8.1.
the skin of the injection the injection 0.52 0.00 0.52 1 8.2.
hypodermic injection 1 injection 0.52 0.00 0.52 8.3.
injection muscle 1 injection 0.52 0.00 0.52 8.4.
injection of vein 1 injection 1.56 0.00 1.56 8.5.
sampling of blood from veins 1 injection 1.04 0.00 1.04 8.6.
vakutainer 1 injection 0.16 0.00 0.16 8.7.
capillary blood sampling with mikrotainer 1 the examination 0.45 0.00 0.45 8.8.
blood sampling in a closed system, 2 vials 1 study 0.65 0.00 0.65 II. Public services that are provided to a person without a family doctor or specialist referral outpatient or inpatient investigation and treatment 9.
Health care outpatient section 9.1.
the professor's advice (first inspection) 1 consultation 35.00 0.00 35.00 9.2.
the professor's advice (see again) 1 consultation 20.00 0.00 20.00 9.3.
Assistant Professor counseling (first inspection) 1 consultation 25.00 0.00 25.00 9.4.
Assistant Professor counseling (re view) 1 consultation 15.00 0.00 15.00 9.5.
infektolog consultation tropical disease (at the time) 1 consultation 8.00 0.00 8.00 9.6.
infektolog consultation tropical disease (out of time) 1 consultation 10.00 0.00 10.00 9.7.
the radiologist consultation 1 study 4.00 0.00 4.00 9.8.
ophthalmologist preventive inspection 1 study 7.85 0.00 7.85 9.9.
preventive examination 1 otorinolaringolog study 6.30 0.00 6.30 9.10.
Occupational medical examination 1 study 6.00 0.00 6.00 9.11.
a certified therapist, Pediatrics, infektolog, dermatovenerolog, ftiziopneimonolog, traumatolog, ortopēd, urolog, psychiatrist, gynecologist, surgeon, thoracic surgeon, neurologist, psychotherapist, hepatolog, otorinolaringolog, ophthalmologist consulting (first inspection) 1 consultation 20.00 0.00 20.00 9.12.
a certified therapist, Pediatrics, infektolog, dermatovenerolog, ftiziopneimonolog, traumatolog, ortopēd, urolog, psychiatrist, gynecologist, surgeon, thoracic surgeon, neurologist, psychotherapist, hepatolog, otorinolaringolog, ophthalmologist consultations (see again) 1 consultation 10.00 0.00 10.00 10.
Otorhinolaryngology 10.1.
nose bleeding with suspension of irritants and/or tamponād, with the use of 1 procedure elektrokauter 10.10 0.00 10.10 10.2.
nasal tamponād from the front 1 procedure 6.49 0.00 6.49 10.3.
foreign bodies from the nose of RIP 1 procedure 9.80 0.00 9.80 10.4.
Haimor cavity puncture the rinsing and medication infusion 1 procedure 3.63 0.00 3.63 10.5.
medication administration of larynx 3.05 0.00 3.05 10.6 procedure 1.
sulphur removal procedure 1 Cork 1.90 0.00 1.90 10.7.
removal of foreign bodies from the hearing procedure 2.29 0.00 2.29 10.8 1 go.
medication administration hearing procedure 2.19 0.00 2.19 10.9 1 aisle.
incision of eardrum 1 procedure 2.59 0.00 2.59 10.10.
medication entering the drum cavity 1 procedure 2.05 0.00 2.05 10.11.
hearing test procedure 1 1.75 0.00 1.75 10.12.
hearing threshold test (audiometrij) 1 10.13 3.75 0.00 3.75 procedure.
virssliekšņ test procedure 1 3.77 0.00 3.77 10.14.
timpanometrij procedure 1 4.65 0.00 4.65 11.
Urology 11.1.
cistoskopij, including uretroskopij and/or biopsy procedure 14.86 0.00 14.86 1

11.2. a woman's urethra 1 procedure 2.80 0.00 2.80 bužēšan 11.3.
the male urethra 1 procedure bužēšan 3.90 0.00 3.90 11.4.
bladder katetrizācij using a single catheter procedure 1 2.30 0.00 2.30 11.5.
bladder flushing, katetrizācij with medication instilācij. Continuous catheter insertion procedure 1 4.57 0.00 4.57 11.6.
bladder flushing, if inserted into a permanent catheter procedure 2.11 0.00 2.11 12 1.
Surgery 12.1.
wound primary finish 1 procedure 3.63 0.00 3.63 12.2.
primary surgical wounds finish, including cutting and sealing procedure 1 8.95 0.00 8.95 12.3.
removal of foreign matter from the wound 1 procedure 4.07 0.00 4.07 12.4.
thread removal procedure 1 1.78 0.00 1.78 12.5.
medication administration, cavity rinsing and strutojoš wound abscess cases 1 procedure 3.74 0.00 3.74 12.6.
superficial tissue puncture biopsy procedure 1 5.39 0.00 5.39 12.7.
Open the bone, muscles, lymph node biopsy surgery procedure 1 30.28 0.00 30.28 12.8.
superficial incision with drainage procedure 1 11.72 0.00 11.72 12.9.
local benign cutaneous and subcutaneous formations of ekstirpācij and superficial tissue biopsy surgery procedure 1 24.22 0.00 24.22 12.10.
local benign cutaneous and subcutaneous formations of ekstirpācij and superficial tissue biopsy ambulatory procedure 1 15.00 0.00 15.00 12.11.
1 joint injections procedure 2.05 0.00 2.05 12.12.
infusion vein 1 procedure 1.92 0.00 1.92 12.13.
bandage 1 procedure 0.50 0.00 0.50 12.14.
the abdominal cavity puncture room 1 procedure 4.92 0.00 4.92 12.15.
pleural cavity puncture with a non-reusable set of 1 procedure 8.65 0.00 8.65 12.16.
lumbar puncture procedure 1 5.48 0.00 5.48 12.17.
bone marrow puncture, using single-use Kit 1 procedure 18.00 0.00 18.00 12.18.
Joint puncture procedure 1 4.00 0.00 4.00 12.19.
spine blockade with drugs injected into the spinal canal 1 procedure 4.45 0.00 4.45 13.
Gynecology 13.1.
gynecologist, preventive inspection specialist 1 study 7.55 0.00 7.55 13.2.
uterine spiral procedure 1 enter 3.30 0.00 3.30 13.3.
uterine spiral removal procedure 1 2.04 0.00 2.04 13.4.
mammary gland inquiry procedure 1 0.80 0.00 0.80 13.5.
the swab sampling of 1 onkocitoloģisk procedure 0.86 0.00 0.86 13.6.
swab sampling of STI diagnosis procedure 1 1.22 0.00 1.22 8.5.
the walls of the vagina and the cervix biopsy procedure 1 12.47 0.00 12.47 13.8.
uterus and preparation of aspiration cytology investigation procedure 1 3.23 0.00 3.23 13.9.
uterine mass correction with rings 1 procedure 2.94 0.00 2.94 27.40.
The glands Bartolin incision procedure 1 14.42 0.00 14.42 13.11.
cervical canal polip removal procedure 1 11.67 0.00 11.67 13.12.
cervical dilation and abrāzij channel in the diagnostic investigation procedure 10.64 0.00 10.64 13.13 1.
uterus abrāzij 1 procedure 10.46 0.00 10.46 13.14.
pussy back arches puncture procedure 5.53 0.00 5.53 14 1.
Hospital profile patient days (without the most rigorous studies Diagnosta) 1-15 days 42.00 0.00 42.00.
Laboratory studies 15.1.
clinical study of 15.1.1.
blood investigation 15.1.1.1.
White (adding the camera) 1 study 0.62 0.00 0.62 15.1.1.2.
retikulocīt (manual) 1 study 1.16 0.00 1.16 15.1.1.3.
platelets (manually) study 1 1.04 0.00 1.04 15.1.1.4.
sink rate of red (EGA) 1 study 0.76 0.00 0.76 15.1.1.5.
Leukocyte formula and erythrocyte morphology 1 study 1.76 0.00 1.76 15.1.1.6.
flowing blood in time after the Duke study 0.70 0.00 0.70 15.1.1.7 method 1.
Red vilkēd (LED) study of cell 1 4.58 0.00 4.58 15.1.1.8.
blood test with a three-part Blood analyser 1 discriminatory study 1.73 0.00 1.73 15.1.1.9.
retikulocīt automated haematology Analyzer in the investigation with 1 study 4.66 0.00 4.66 15.1.1.10.
blood analysis with five-part Blood analyser 1 discriminatory study 3.00 0.00 3.00 15.1.1.11.
blood analysis with five-part of the analyser and discriminatory blood red cells sink rate (EG) discovery 1 study 3.76 0.00 3.76 15.1.1.12.
blood analysis, determination of retikulocīt with five-part of the analyser and discriminatory blood red cells sink rate (EG) study 1 8.42 0.00 8.42 15.1.1.13 determination.
blood analysis with five-part of the analyser, the discriminatory blood retikulocīt detection and manual erythrocyte sink rate (EG) discovery 1 study 4.92 0.00 4.92 15.1.1.14.
flowing blood time after methods 1 study 2.55 0.00 2.55 lvy 15.1.2.
urine investigation 15.1.2.1.
physical examination 1 study 0.16 0.00 0.16 15.1.2.2.
protein (quantitative) study 1 1.24 0.00 1.24 15.1.2.3.
quantitative microscopy 1 sediment study 1.45 0.00 1.45 15.1.2.4.
urine analysis with strip (environmental level (pH), proteins, sugar, acetone, bilirubin, urobilinogēn, blood) 1 study 0.87 0.00 0.87 15.1.2.5.
analysis of urine with the strip, physical and mikroskopēšan study of sediment 1 2.16 0.00 2.16 15.1.2.6.
determination of specific weight of urine with 1 urometr study 0.18 0.00 0.18 15.1.3.
clinical investigation of likvor 1 the examination 2.51 0.00 2.51 15.1.4.
sputum examination 15.1.4.1.
clinical analysis of sputum examination will 15.1.4.2 1.91 0.00 1.91 1.
mikobaktērij bakterioskopisk of investigation 1 study 2.32 0.00 2.32 15.1.4.3.
eozinofil-white sputum examination 1.00 0.00 1.00 1 15.1.5.
investigation of faecal 15.1.5.1.
koprogramm 1 the examination 1.82 0.00 1.82 15.1.5.2.
a study of latent blood 1 0.44 0.00 0.44 15.1.5.3.
bile pigments 1 study 15.1.5.4 0.40 0.00 0.40.
hidden blood in the teststrēmel (imūnhromatogrāfij) 1 study 1.10 0.00 1.10 15.1.6.
the serous cavities and the cyst fluid analysis in study 1 clinical 1.91 0.00 1.91 15.1.7.
cytological studies 15.1.7.1.
the swab of cervical onkocitoloģisk (1 product) channel and back arches 1 study 2.10 0.00 2.10 15.1.7.2.
cytological studies of cervical canal (3 products) 1 study 2.92 0.00 2.92 15.1.7.3.
cytological studies of abdominal cavity, pleural and Douglas, the uterine cavity (3 products) 1 study 5.00 0.00 5.00 15.1.7.4.
urine or bladder washings for cytology investigation (5 formulations) 1 study 3.86 0.00 3.86 15.1.7.5.
sputum cytology investigation (3 products) 1 study 3.67 0.00 3.67 15.2.
biochemical studies 15.2.1.
blood investigation 15.2.1.1.
bilirubin, fractions 1 study 1.75 0.00 1.75 15.2.1.2.
alanīnaminotransferāz 1 the examination 1.41 0.00 1.41 15.2.1.3.
aspartātaminotransferāz 1 the examination 1.41 0.00 1.41 15.2.1.4.
alkaline phosphatase 1 study 1.41 0.00 1.41 15.2.1.5.
Alpha-1 amilāz study 15.2.1.6 2.35 0.00 2.35.
gammaglutamiltransferāz 1 the examination 15.2.1.7 1.73 0.00 1.73.
kreatīnkināz 1 the examination 2.22 0.00 2.22 15.2.1.8.
urea (bun) 1 study 1.43 0.00 1.43 15.2.1.9.
1 study 1.43 0.00 1.43 creatinine 15.2.1.10.
uric acid study 1.55 0.00 1.55 15.2.1.11 1.
protein (total) 1 study 1.06 0.00 1.06 15.2.1.12.
albumin 1 study 15.2.1.13 1.12 0.00 1.12.
protein fractions 1 study 4.36 0.00 4.36 15.2.1.14.
glucose blood study 0.97 0.00 0.97 15.2.1.15 1.
glucose loading test 1 study 3.31 0.00 3.31 15.2.1.16.
cholesterol total 1 study 1.46 0.00 1.46 15.2.1.17.
triglycerides study 1.79 0.00 1.79 15.2.1.18 1.
C-reactive protein (quantitative) study 2.61 0.00 2.61 15.2.1.19 1.
for 5.12 0.00 5.12 15.2.1.20 ferritīn 1 the examination.
by antistreptolizīn-0 (high quality) 1 study 1.73 0.00 1.73 15.2.1.21.
determination of ethanol by enzymatic study 4.50 0.00 4.50 15.2.1.22 1.
potassium 1 study 1.68 0.00 1.68 15.2.1.23.
sodium 1 study 1.68 0.00 1.68 15.2.1.24.
calcium 1 study 1.43 0.00 1.43 15.2.1.25.
study of iron 1 1.58 0.00 1.58 15.2.1.26.
Iron binding capacity study 2.25 0.00 2.25 1 15.2.1.27.
copper in the blood 1 study 2.97 0.00 2.97 15.2.1.28.
free (FT4) 1 tiroksīn study 15.2.1.29 4.06 0.00 4.06.
free (FT3) 1 trijodtironīn study 15.2.1.30 4.06 0.00 4.06.
the tireotrop hormone (TSH) 1 study 3.93 0.00 3.93 15.2.1.31.
Reduced Glutathione study 11.98 0.00 11.98 15.2.1.32 1.
rheumatoid factor (high quality) 1 study 1.52 0.00 1.52 15.2.1.33.
high density lipoproteins (HDL) cholesterol study 1.94 0.00 1.94 15.2.1.34 1.
low density lipoprotein (LDL) cholesterol study 2.44 0.00 2.44 15.2.1.35 1.
apolipoproteīn A1 1 study 2.81 0.00 2.81 15.2.1.36.
apolipoproteīn B 1 study 2.81 0.00 2.81 15.2.1.37.
soluble transferīn receptor study 6.43 0.00 6.43 15.2.1.38 1.
the cardiac troponin T (acute myocardial infarction Express) 1 study 5.29 0.00 5.29 15.2.1.39.
Myoglobin in

1 study 4.89 0.00 4.89 15.2.1.40.
insulin study 4.57 0.00 4.57 15.2.1.41 1.
hyaluronic acid 1 study 10.51 0.00 10.51 15.2.1.42.
citokeratīn 18 (CK 18 neo-epitopes) 7.70 0.00 7.70 1 study 15.2.1.43.
cytochrome c 1 study 10.57 0.00 10.57 12.2.1.44.
endotoxin core antibody (quantitative) study 7.69 0.00 7.69 15.2.1.45 1.
nitrates/nitrites quantitative study 6.22 0.00 6.22 15.2.1.46 1.
blood gas and environmental level (pH) analysis study 12.25 0.00 12.25 15.2.1.47 1.
serum (plasma) getting 1 study 0.39 0.00 0.39 15.2.1.48.
magnesium 1 study 1.20 0.00 1.20 15.2.1.49.
laktātdehidrogenāz 1 the examination 15.2.1.50 1.10 0.00 1.10.
troponin T 1 study 4.80 0.00 4.80 15.2.1.51.
a qualitative study of antistreptolizīn 1 15.2.1.52 1.12 0.00 1.12.
determination of IgG immunoglobulin 1 study 2.00 0.00 2.00 15.2.1.53.
immunoglobulin a IGA determination study 2.10 0.00 2.10 15.2.1.54 1.
detection of immunoglobulin IgM 1 study 2.20 0.00 2.20 15.2.2.
a study of likvor 15.2.2.1.
chlorides 1 study 1.40 0.00 1.40 15.2.2.2.
protein (quantitative) study 1 0.79 0.00 0.79 15.2.2.3.
glucose (quantitative) study 1 0.79 0.00 0.79 15.2.3.
punktāt investigation (protein (total)) 1 study 1.06 0.00 1.06 15.2.4.
imūnhematoloģij studies of 15.2.4.1.
determination of blood group ABO system with planes method (dubultreakcij) (A and B antigen detection by direct reaction, anti-A and anti-B antibodies with the inverse reaction) 1 study 1.56 0.00 1.56 15.2.4.2.
rhesus factor (Rh (D)) signs with planes method (with two reagents) 1 study 1.64 0.00 1.64 15.2.4.3.
rhesus factor (Rh (D)) features detection geltehnik (with one reagent) 1 study 1.78 0.00 1.78 15.2.4.4.
not full antieritrocitār antibody screening geltehnik (ID card List/Coomb) 1 study 3.07 0.00 3.07 15.2.4.5.
determination of blood group ABO system with planes method (direct response) (A and B antigen with direct response) 1 study 0.86 0.00 0.86 15.2.4.6.
determination of blood group ABO and rhesus factor (Rh) system in geltehnik (A and B antigen detection by direct reaction, anti-A and anti-B antibodies with the inverse reaction, D Antigen) 1 study 3.74 0.00 3.74 15.2.4.7.
rhesus factor (Rh) system phenotype (CcE) and the determination of the Kell geltehnik 15.2.4.8 in study 1 5.68 0.00 5.68.
of the recipient and the donor's blood test in the individual compatibility Lab (ABO, rhesus factor (Rh) and other systems-geltehnik) 1 study 7.73 0.00 7.73 15.2.4.9.
a direct test of the anti-human globulin – (data) geltehnik (ID card List/Coomb) 1 study 1.97 0.00 1.97 15.2.5.
koaguloģij tests 15.2.5.1.
protrombīn index (INR) 1 study 15.2.5.2 1.62 0.00 1.62.
the activated partial tromboplastīn time (APTL) 1 study 1.79 0.00 1.79 15.2.5.3.
Fibrinogen 1 study 1.79 0.00 1.79 15.2.5.4.
Thrombin time 1 study 1.74 0.00 1.74 15.2.6.
urine investigation 15.2.6.1.
glukuronīd in urine 1 study 15.46 0.00 15.46 15.2.6.2.
protein (quantitative) study 0.79 0.00 0.79 15.2.6.3 1.
glucose (quantitative) study 0.79 0.00 0.79 15.2.6.4 1.
Alpha-1 amilāz study 15.2.6.5 2.35 0.00 2.35.
study of iron 1 1.58 0.00 1.58 15.2.6.6.
calcium 1 study 1.43 0.00 1.43 15.2.6.7.
urea (bun) 1 study 1.43 0.00 1.43 15.2.6.8.
1 study 1.43 0.00 1.43 creatinine 15.2.6.9.
uric acid study 1.55 0.00 1.55 15.2.6.10 1.
determination of ethanol by enzymatic study 4.50 0.00 4.50 15.2.6.11 1.
drugs and their offspring Morrow ekspresdiagnostik test (panel of four substances) 1 study 4.04 0.00 4.04 15.2.6.12.
drugs and their offspring Morrow ekspresdiagnostik test (panel of eight substances) 1 study 6.57 0.00 6.57 15.2.7.
testing with dry chemistry analyser REFLOTRON 15.2.7.1.
determination of cholesterol by dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 15.2.7.2.
bilirubin determination by dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 15.2.7.3.
alanīnminotransferāz (AL) with dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 15.2.7.4.
aspartātaminotransferāz (S) with dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 15.2.7.5.
determination of triglycerides with dry chemistry analyser REFLOTRON 1 study 2.01 0.00 2.01 15.2.7.6.
pankreātisk determination of amylase by dry chemistry analyser 1 study IV 2.23 0.00 2.23 REFLOTRON 15.2.7.7.
determination of glucose by dry chemistry analyser REFLOTRON IV 1 study 15.2.7.8 1.90 0.00 1.90.
high density lipoproteins (HDL)-cholesterol determination by dry chemistry analyser REFLOTRON 1 study 2.12 0.00 2.12 15.2.7.9.
determination of urea (bun) with dry chemistry analyser 1 study IV 2.17 0.00 2.17 REFLOTRON 15.2.7.10.
determination of the concentration of creatinine with dry chemistry analyser 1 study IV 2.09 0.00 2.09 REFLOTRON 15.2.7.11.
alpha-amylase activity detection with dry chemistry analyser REFLOTRON IV 1 study 2.43 0.00 2.43 15.2.7.12.
determination of potassium with dry chemistry analyser 1 study IV 2.23 0.00 2.23 REFLOTRON 15.2.7.13.
gammaglutamīntransferāz (GG) activity detection with dry chemistry analyser REFLOTRON IV 1 study 2.02 0.00 2.02 15.3.
parasitological studies 15.3.1.
blood parasite (malaria, filariidoz) thick drops of 1 study 7.36 0.00 7.36 15.3.2.
Malaria blood smear pazmodij 1 the examination 8.27 0.00 8.27 15.3.3.
Blood of Plasmodi Ag (imūnhromatogrāfij) 1 study 4.91 0.00 4.91 15.3.4.
analysis on the helminth (Kato) 1 study 1.58 0.00 1.58 15.3.5.
scrape from perianālaj folds to spalīš eggs 1 study 0.91 0.00 0.91 15.3.6.
investigation of enterobioz with adhesive tape method 1 study 1.86 0.00 1.86 15.3.7.
Pneumocyst a jiroveci (carini) Ag (IF)-Pneumocyst by jiroveci (carini) Antigen with indirect imūnfluorescenc microscopy study of 1 of 13.60 0.00 13.60 15.3.8.
Cryptosporidium Ag with faeces (ELISA), Cryptosporidium Antigen with immune enzymatic reaction 1 study 15.3.9 5.99 0.00 5.99.
lamblij and helminth determination of bile in preparation for native and sediment (three servings) 1 study 6.58 0.00 6.58 15.3.10.
protozoa and helminth cyst investigation with enrichment (concentration) method 4.13 0.00 4.13 15.3.11 1 study.
scabbers mite, dziedzerērc 1 the examination 5.28 0.00 5.28 15.3.12.
helmint and determination of their snippet 1 study 2.31 0.00 2.31 15.3.13.
intestinal protozoa parasite detection in preparation of the study natīv 1 15.3.14 2.79 0.00 2.79.
Anti-Toxocar-Canis IgG (ELISA) immunoglobulin G antibodies to the class of cērmj larvae of the dog study 4.26 0.00 4.26 15.3.15 1.
Anti-Trichinella spiralis (ELISA) immunoglobulin IgG-class G antibodies against Trichinella examination 4.26 0.00 4.26 15.3.16 1.
Echinococcus anti-IgG (ELISA) species: immunoglobulin G antibodies to the class of ehinokok species (e. granulos, e. multilokular) 1 study 7.81 0.00 7.81 15.3.17.
Echinococcus granulosus anti-IH-HA antibody reaction to the study of the unicameral ehinokok 1 8.80 0.00 8.80 15.3.18.
The compatible lambli (Ag faeces) (ELISA)-lamblij with imūnfermentatīv of Antigen reaction 1 study 5.99 0.00 5.99 15.3.19.
Entamoeb-anti-hystolitic-IH-HA antibody reaction to the hystolitic Entamoeb (the dysentery Amoeba) 1 study 10.76 0.00 10.76 15.3.20.
Entamoeb hystolitic Ag in the faeces (ELISA) – the Amoeba dysentery Antigen with imūnfermentatīv response 1 study 6.61 0.00 6.61 15.3.21.
Anti-IgG (ELISA) of Taenia-immunoglobulin G antibodies against the class of the pig tapeworm larvae study 8.67 0.00 8.67 1 15.3.22.
Cysticercos by WB-cisticerk IgG immunoglobulin G antibody present approval with the ses Western blot reaction study 35.17 0.00 35.17 15.3.23 1.
Toxocar WB toksokar immunoglobulin G IgG-class antibody validation by Western blot reaction 1 study 31.72 0.00 31.72 15.3.24.
Trichinae Trichinella WB IgG-class antibody immunoglobulin G approval by Western blot reaction study 35.17 0.00 35.17 15.3.25 1.
Echinoccoc-WB IgG immunoglobulin G ehinokok-class antibody to youth with the US Western blot reaction 1 study 35.17 0.00 35.17 15.4.
veneroloģisk studies 15.4.1.
Chlamidi trachomatis Antigen (IFA)-Chlamidi trachomatis Antigen with immune fluorescence reaction 1 study 4.68 0.00 4.68 15.4.2.
Chlamidi trachomatis Antigen (ELISA) – Chlamidi trachomatis Antigen with imūnfermentatīv response 1 study 8.89 0.00 8.89 15.4.3.
Trichomonas from vaginal set in preparation of the study natīv 1 1.21 0.00 1.21 15.4.4.

gynecological smears in 1 study 2.10 0.00 2.10 15.4.5.
syphilis-diagnosis (of Treponema pallidum) HA (TPH) 1 study 15.4.6 2.10 0.00 2.10.
syphilis-diagnosis (of Treponema pallidum) HA (TPH) by titration 1 study 4.41 0.00 4.41 15.4.7.
Demonstration of Treponema pallidum by dark field microscopy 1 study 1.65 0.00 1.65 15.4.8.
syphilis Diagnostics-reagīn of precipitation (RPR) 1 study 1.46 0.00 1.46 15.4.9.
syphilis Diagnostics-reagīn of precipitation (RPR) with titration 1 study 4.51 0.00 4.51 15.4.10.
plating on Mycoplasma 1 study 6.73 0.00 6.73 15.4.11.
plating on ureaplazm 1 the examination 6.73 0.00 6.73 15.4.12.
plating on gonococcal (positive) 1 study 10.40 0.00 10.40 15.4.13.
plating on gonococcal (negative) 1 study 6.75 0.00 6.75 15.4.14.
reagīn precipitin reaction (RPR) 1 hour study 4.28 0.00 4.28 15.4.15.
sexually transmitted diseases (STDs) in the film the hour 1 study 3.75 0.00 3.75 15.4.16.
certificate to the syphilis study 1 3.05 0.00 3.05 15.4.17.
certificate-duplicate for syphilis to 1 study 3.62 0.00 3.62 15.4.18.
Chlamidi trachomatis Antigen confirmatory test (ELISA) – Chlamidi trachomatis Antigen approval with imūnfermentatīv response 1 study 16.02 0.00 16.02 15.4.19.
Mycoplasma or ureaplazm determination of sensitivity to antibiotics 1 study 5.79 0.00 5.79 15.5.
hepatitis diagnostic 15.5.1.
Anti-HAV: antibody (ELISA) against hepatitis A virus through a study of the reaction of 1 imūnfermentatīv 5.50 0.00 5.50 15.5.2.
Anti-HAV IgM (ELISA) immunoglobulin M antibodies against viral hepatitis in class A with imūnfermentatīv response 1 study 6.30 0.00 6.30 15.5.3.
HAVE Ag (ELISA)-hepatitis A virus Antigen with imūnfermentatīv response 1 study 7.75 0.00 7.75 15.5.4.
HBS Ag (ELISA)-hepatitis B virus surface antigen with imūnfermentatīv response 1 study 3.43 0.00 3.43 15.5.5.
HBS Ag confirmatory test (ELISA) – viral hepatitis B surface antigen positive test 1 study 8.28 0.00 8.28 15.5.6.
Anti-HBS quantitative antibody (ELISA) against viral hepatitis B determination with imūnfermentatīv response 1 study 7.55 0.00 7.55 15.5.7.
Anti-HBc antibody (ELISA) against viral hepatitis B core Antigen immuno-enzymatic reaction with 1 study 6.05 0.00 6.05 15.5.8.
Anti-HBc IgM (ELISA) immunoglobulin M antibodies against viral hepatitis of class B core Antigen with imūnfermentatīv response 1 study 6.47 0.00 6.47 15.5.9.
HBE Ag (ELISA) – viral hepatitis B E Antigen with imūnfermentatīv response 1 study 7.52 0.00 7.52 15.5.10.
Anti-HBE antibody (ELISA) against viral hepatitis B E Antigen with imūnfermentatīv response 1 study 7.52 0.00 7.52 15.5.11.
Anti-HCV (ELISA) – antibody against viral hepatitis C with imūnfermentatīv response 1 study 6.80 0.00 6.80 15.5.12.
Anti-HCV positive test (WB) – antibody against viral hepatitis C approval by Western blot reaction study 44.57 0.00 44.57 15.5.13 1.
HCV RNA (PCR) – hepatitis C virus ribonukleīnskāb detection with polymerase chain reaction study 51.30 0.00 51.30 15.5.14 1.
HD Ag (ELISA)-Hepatitis delta virus Antigen with imūnfermentatīv response 1 study 5.95 0.00 5.95 15.5.15.
Anti-HD (ELISA) immunoglobulin IgM-class antibodies against M Hepatitis delta virus detection with imūnfermentatīv response 1 study 5.95 0.00 5.95 15.5.16.
AFP (ELISA)-alpha-fetoproteīn detection with imūnfermentatīv response 1 study 15.5.17 4.69 0.00 4.69.
HBS Ag (ELISA)-Other viral hepatitis B surface antigen detection with imūnfermentatīv quick response two hours 1 study 9.32 0.00 9.32 15.5.18.
Anti-HAV IgM, the Other (ELISA) immunoglobulin M antibodies against viral hepatitis class A quick determination by imūnfermentatīv response two hours 1 study 12.37 0.00 12.37 15.5.19.
Anti-HBc (ELISA) – Other antibodies against viral hepatitis B core Antigen two hours 1 study 12.19 0.00 12.19 15.5.20.
Anti-HCV (ELISA) – Other antibodies against viral hepatitis C quick determination by immune enzymatic reaction within two hours of study 1 13.02 0.00 13.02 15.5.21.
HBS Ag certificate (ELISA) – viral hepatitis B surface antigen with imūnfermentatīv response 1 study 5.18 0.00 5.18 15.5.22.
HBS Ag certificate (ELISA) – viral hepatitis B surface antigen with imūnfermentatīv response two hours 1 study 8.28 0.00 8.28 15.5.23.
Anti-HD (ELISA) immunoglobulin IgG-class antibodies against G Hepatitis delta virus detection with imūnfermentatīv response 1 study 5.95 0.00 5.95 15.5.24.
HCV RNA load (PCR) – viral hepatitis C ribonukleīn acid determination by polymerase chain reaction study 105.34 0.00 105.34 15.5.25 1.
HCV genotipēšan (molecular hybridization) viral hepatitis C genotype detection study 147.89 0.00 147.89 15.5.26 1.
HBV DNA (PCR) load-viral hepatitis B dezoksirib determination of nucleic acid by polymerase chain reaction study 88.83 0.00 88.83 15.5.27 1.
Anti-HEV IgM (ELISA) immunoglobulin M antibodies against viral hepatitis of class E with imūnfermentatīv response 1 study 12.87 0.00 12.87 15.5.28.
Anti-HEV IgG (ELISA) immunoglobulin G antibodies against viral hepatitis of class E with imūnfermentatīv response 1 study 9.71 0.00 9.71 15.6.
HIV/AIDS Diagnostics 15.6.1.
Anti-HIV 1/2 by express method-antibody against human immunodeficiency virus 1 and 2 with quick determination method 1 study 4.22 0.00 4.22 15.6.2.
Anti-HIV 1/2 to the certificate (ELISA) – antibody against human immunodeficiency virus 1 and 2 with imūnfermentatīv response 1 study 10.01 0.00 10.01 15.6.3.
Anti-HIV 1/2 with certificate and duplicate (ELISA) – antibody against human immunodeficiency virus 1 and 2 with imūnfermentatīv response 1 study 10.70 0.00 10.70 15.6.4.
Anti-HIV 1/2 with the quick method, and a certificate – antibody against human immunodeficiency virus 1 and 2 with quick determination method 1 study 11.73 0.00 11.73 15.6.5.
Anti-HIV 1/2 with the quick method, the certificates and duplicates – antibody against human immunodeficiency virus 1 and 2 with quick determination method 1 study 12.42 0.00 12.42 15.6.6.
Anti-HIV 1/2 antibody (ELISA) against human immunodeficiency virus 1 and 2 with imūnfermentatīv response 1 study 4.53 0.00 4.53 15.6.7.
HIV load (HIV RNA Kwan.) (PCR) – HIV RNA quantification with PCR-1 study 109.50 0.00 109.50 15.6.8.
Anti-HIV 1/2 Ag (ELISA) and HIV-antibody against at the human immunodeficiency virus 1 and 2 and the human imūndef virus Antigen deficits through imūnfermentatīv response 1 study 4.53 0.00 4.53 15.6.9.
Anti-HIV-1 and/or 2 the confirmatory test for antibodies against the WB-human immunodeficiency virus 1 and 2 approval by Western blot reaction 1 examination 31.36 0.00 31.36 15.6.10.
Ag (ELISA)-HIV human immunodeficiency virus Antigen with imūnfermentatīv response 1 study 15.62 0.00 15.62 15.6.11.
HIV confirmatory test Ag (ELISA with neutralization), human immunodeficiency virus Antigen approval with imūnfermentatīv reaction with neutralization 1 study 40.23 0.00 40.23 15.6.12.
HIV (human immunodeficiency virus) genotipēšan resistance detection (sequencing) 1 study 441.62 0.00 441.62 15.7.
15.7.1 the immunological studies.
imūnstatus-determination of lymphocyte imunofenotip quantitative (absolute number,%) (CD3/CD4/CD8 CD3, CD16 + CD3 CD56 CD19, HLA-DR, HLA-DR CD3/), 1 study flow citometrij 29.92 0.00 29.92 15.7.2.
t-lymphocytes in the imunofenotip determination (absolute number,%) (CD3/CD4/CD8 CD3), flow citometrij study 1 24.54 0.00 24.54 15.7.3.
imūnregulējoš determination of cells (CCR5), CD195 flow citometrij study 1 8.91 0.00 8.91 15.7.4.
the human Antigen B count tipēšan by molecular hybridization (HLA B-human leucocyt antigen of B) 1 study 107.33 0.00 107.33 15.8.
Herpes group virus infection Diagnostics 15.8.1.
Anti-CMV IgG quantitative (ELISA) immunoglobulin G antibody against another class through the megalovīrus reaction imūnfermentatīv 1 the examination 7.97 0.00 7.97 15.8.2.
Anti-CMV IgM (ELISA) immunoglobulin M antibodies against citomegalovīrus of class through the imūnfermentatīv reaction 1 study 6.52 0.00 6.52 15.8.3.
Anti-HSV IgM (ELISA) immunoglobulin M antibody class against herpes simplex virus type 1 and 2 with imūnfermentatīv response 1 study 6.10 0.00 6.10 15.8.4.
HSV1/2 Ag IF – herpes simplex virus 1 and 2 types of Antigen detection by microscopy study of imūnfluorescenc 1 7.89 0.00 7.89 15.8.5.

Anti-IgG quantitative HSV1/2 (ELISA) immunoglobulin G class antibodies against herpes simplex type 1 and 2 a quantification with imūnfermentatīv response 1 study 6.74 0.00 6.74 15.8.6.
Anti-VZV (HZV) IgM (ELISA) immunoglobulin M antibodies against Varicell of the class (or herpes zoster) zoster virus detection with imūnfermentatīv response 1 study 7.45 0.00 7.45 15.8.7.
Anti-VZV (HZV) IgG quantitative (ELISA) immunoglobulin G antibody-class against the Varicell (or herpes zoster) zoster virus identification with imūnfermentatīv response 1 study 8.82 0.00 8.82 15.8.8.
Anti-CMV IgG aviditāt (ELISA) immunoglobulin G antibodies against citomegalovīrus of class aviditāt with imūnfermentatīv determination of reaction 1 study 8.79 0.00 8.79 15.8.9.
CMV DNA quantitative (PCR-RL) – citomegolovīrus's (CMV DNA) DNA quantification with PCR in real time study 1st 44.63 0.00 44.63 15.8.10.
CMV DNA (PCR) – quality of the nucleic acid citomegalovīrus dezoksirib (CMV DNA) identification with polymerase chain reaction study 15.88 0.00 15.88 15.8.11 1.
Anti-EBV EA (ELISA) immunoglobulin IgM-class antibodies against M Epstein-Barr virus early Antigen detection with imūnfermentatīv response 1 study 5.18 0.00 5.18 15.8.12.
Anti-EBV EA IgG quantitative (ELISA) immunoglobulin G antibody against Epstein present ses-Barr virus early Antigen determination in the light of the kvantit with the immune reaction of enzymatic study 5.18 0.00 5.18 15.8.13 1.
Anti-VCA IgM EBV (ELISA) immunoglobulin M antibody against Epstein in class-Barr viral antigen detection by a skin reaction 1 imūnfermentatīv study 15.8.14 4.95 0.00 4.95.
Anti-VCA IgG EBV quantitatively (ELISA) immunoglobulin G antibody against Epstein present ses-Barra viral skin Antigen determination with imūnfermentatīv response 1 study 6.93 0.00 6.93 15.8.15.
Anti-EBV IgG quantitative EBN (ELISA) immunoglobulin G antibody against Epstein in class-Barr virus nuclear antigen determination with imūnfermentatīv response 1 study 6.46 0.00 6.46 7.8.16.
Anti-EBV IgM, WB-immunoglobulin M antibody against Epstein in class-Barra viral validation by Western blot reaction study 31.67 0.00 31.67 15.8.17 1.
Anti-EBV IgG immunoglobulin G, WB-class antibodies against Epstein-Barr virus confirmation with Western blot reaction study 31.67 0.00 31.67 15.8.18 1.
EBV DNA quantitative (PCR-RL), Epstein-Barr virus DNA (DNA) identification by PCR in real time study 1st 44.63 0.00 44.63 15.8.19.
EBV DNA (PCR) quality-Epstein-Barr virus (EBV) DNA (DNA) detection quality with polymerase chain reaction study 15.88 0.00 15.88 15.8.20 1.
HSV 1/2 DNA quantitative (PCR-RL)-Herpes simplex type 1 and 2 dezoksiribonukleīn acid determination by quantitative polymerase chain reaction real time study 1st 44.63 0.00 44.63 15.8.21.
HSV1/2 DNA (PCR) quality – herpes simplex 1 and 2 subtip of dezoksiribonukleīn acid (DNA) of high quality with polymerase chain reaction study 15.88 0.00 15.88 15.8.22 1.
herpes virus isolation and tipēšan (tissue culture) study 15.8.23 1 23.71 0.00 23.71.
immunoglobulin M antibodies against T.O.R.C.H. class group infections (toxoplasmosis, rubella, herpes infections and citomegalovīrus) by Western blot reaction study 31.67 0.00 31.67 15.8.24 1.
VZV (HZV) DNA quantitative (PCR-RL) – Varicell's (or herpes zoster) zoster virus DNA from say with quantitative polymerase chain reaction real time study 44.63 0.00 44.63 15.8.25 1.
VZV (HZV) DNA (PCR) – quality of Varicell (or herpes zoster) zoster virus DNA detection by polymerase chain reaction 1 study 15.88 0.00 15.88 15.9.
respiratory viral infection Diagnostics 15.9.1.
(A) influenza virus Antigen by imūnfluorescenc 1 the examination 8.24 0.00 8.24 15.9.2.
Influenza virus b Antigen with imūnfluorescenc 1 the examination 8.24 0.00 8.24 15.9.3.
Influenza virus a/B ribonukleīnskāb (RNA) of high quality with polymerase chain reaction in study 1, 27.60 0.00 27.60 15.9.4.
Influenza virus a/B ribonukleīnskāb (RNA) of high quality with polymerase chain reaction real time study 1st 44.63 0.00 44.63 15.9.5.
A flu virus detection quality with subtip polymerase chain reaction, if A flu virus RNA (RNA) is positive 1 study 27.60 0.00 27.60 15.9.6.
A flu virus subtip discovery with polymerase chain reaction in real time if A flu virus RNA (RNA) is positive 1 study 44.63 0.00 44.63 15.9.7.
paragrip viral antigen detection by imūnfluorescenc 1 the examination 8.19 0.00 8.19 15.9.8.
paragrip virus tipēšan with imūnfluorescenc 1 the examination 15.26 0.00 15.26 15.9.9.
adenovīrus the Antigen with imūnfluorescenc 1 the examination 8.22 0.00 8.22 15.9.10.
adenovīrus isolation from clinical material 1 study 23.33 0.00 23.33 15.9.11.
complement fixation detection of adenovīrus 1 the examination 8.05 0.00 8.05 15.9.12.
respirators in virus Antigen sincitiāl (RSV, Ag) detection with imūnfluorescenc 1 the examination 8.24 0.00 8.24 15.9.13.
Anti-RSV IgM (ELISA) immunoglobulin M antibodies against respiratory class in virus detection with sincitiāl imūnfermentatīv response 1 study 6.43 0.00 6.43 15.9.14.
haemagglutination (HA) inhibition with one Antigen (influenza A/H1N1, A/H3N2, B, paragrip I, II, III type) 1 study 7.16 0.00 7.16 15.9.15.
influenza virus isolation in tissue culture and tipēšan 1 the examination 23.12 0.00 23.12 15.9.16.
the human meta pneumo (hMPV) determination by imūnfluorescenc 1 the examination 9.74 0.00 9.74 15.10.
acute viral gastroenteritis diagnostic 15.10.1.
adenovīrus Ag (ELISA)-adenovīrus with imūnfermentatīv the Antigen response 1 study 7.06 0.00 7.06 15.10.2.
rotavirus Ag (ELISA)-rotavirus Antigen with imūnfermentatīv response 1 study 7.06 0.00 7.06 15.10.3.
astrovīrus Ag (ELISA)-astrovīrus with imūnfermentatīv the Antigen response 1 study 7.06 0.00 7.06 15.10.4.
programme identifying norovirus Ag (ELISA) – a programme identifying norovirus Antigen with imūnfermentatīv response 1 study 9.46 0.00 9.46 15.10.5.
programme identifying norovirus ribonukleīnskāb (RNA) of the detection quality with polymerase chain reaction 1 study 15.88 0.00 15.88 15.11.
15.11.1 involved infections Diagnostics.
the withdrawal and the involved tipēšan 1 study 33.10 0.00 33.10 15.11.2.
complement fixation detection of 1 the study involved 8.05 0.00 8.05 15.11.3.
involved in RNA (PCR-RL) quantitative-of the determination involved ribonukleīnskāb by polymerase chain reaction real time study 1st 44.63 0.00 44.63 15.11.4.
involved in RNA (PCR)-the quality of the identification of the involved ribonukleīnskāb by polymerase chain reaction 1 study 15.88 0.00 15.88 15.11.5.
the distribution of involved tissue culture study 1 23.33 0.00 23.33 15.11.6.
neutralization reaction tissue culture with poliovīrus type 1 study 8.67 0.00 8.67 15.11.7.
Anti-a antibodies involved with imūnfermentatīv response 1 study 8.15 0.00 8.15 15.12.
tick-transmitted infection diagnosis 15.12.1.
Anti-TBE IgM likvor (ELISA) immunoglobulin M antibodies against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 5.97 0.00 5.97 15.12.2.
Anti Borrelia burgdorferi IgG immunoglobulin G (WB)-class antibodies against Borrelia burgdorferi approval by Western blot reaction 1 study 24.02 0.00 24.02 15.12.3.
Anti-TBE IgM (ELISA) immunoglobulin M antibodies against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 6.90 0.00 6.90 15.12.4.
Anti-TBE-IgG (ELISA) immunoglobulin G antibody against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 7.71 0.00 7.71 15.12.5.
Anti-Ehrlichi (Anaplasm) with imūnfluorescenc in study 1 IgG 12.67 0.00 12.67 15.12.6.
Anti-Ehrlichi (Anaplasm) imūnfluorescenc 1 the examination with IgM 12.67 0.00 12.67 15.12.7.
Anti Borrelia burgdorferi IgM (ELISA) immunoglobulin M antibody class against Borrelia burgdorferi determination by imūnfermentatīv response 1 study 6.80 0.00 6.80 15.12.8.
Anti Borrelia burgdorferi IgG quantitative (ELISA) immunoglobulin G class antibodies against Borrelia burgdorferi determination by imūnfermentatīv response 1 study 7.19 0.00 7.19 15.12.9.
Anti Borrelia burgdorferi IgM (WB) – immunoglobulin M antibody class against Borrelia burgdorferi approval by Western blot reaction 1 study 24.02 0.00 24.02 15.12.10.
Borrelia DNA (PCR-RL) – Borrelia dezoksiribonukleīn acid detection with polymerase chain reaction real time study 1st 49.57 0.00 49.57 15.13.

rare and imported infections the serological and molecular biological diagnostic 7.13.1.
Anti-virus IgM Hunt (ELISA) immunoglobulin M antibodies against the hunt class virus detection with imūnfermentatīv response 1 study 15.56 0.00 15.56 15.13.2.
Anti-Hunt (ELISA) immunoglobulin IgG-class antibodies against G Hunt virus detection with imūnfermentatīv response 1 study 16.99 0.00 16.99 15.13.3.
Anti-IgM burett of Coxiell (Q fever, ELISA) immunoglobulin M antibodies against Coxiell of the class of antigens by burnett imūnfermentatīv response 1 study 16.32 0.00 16.32 15.13.4.
Anti-IgG burnett of Coxiell (Q fever, ELISA) immunoglobulin G class anti-Coxiell of substances against burnett in the Antigen detection with imūnfermentatīv response 1 study 16.99 0.00 16.99 15.13.5.
The pneumophil's of anti-IgM Legionell (ELISA) immunoglobulin M antibodies against class a pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0.00 9.44 15.13.6.
Anti-pneumophil of IgG Legionell (ELISA) immunoglobulin G antibody against the class of the pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0.00 9.44 15.13.7.
Anti-Deng-IgM (ELISA) immunoglobulin M antibody-class against the virus by Deng imūnfermentatīv response 1 study 12.45 0.00 12.45 15.13.8.
Anti-Deng-IgG (ELISA) immunoglobulin G antibody-class against the virus by Deng imūnfermentatīv response 1 study 12.45 0.00 12.45 15.13.9.
Deng is RNA (PCR-RL)-Deng-ribonukleīnskāb detection of virus by PCR in real time study 1st 63.10 0.00 63.10 15.13.10.
Anti-Puumal (ELISA) of IgM-class antibodies of immunoglobulin M against Puumal virus detection with imūnfermentatīv response 1 study 16.10 0.00 16.10 15.13.11.
Anti-West-Nile (ELISA) immunoglobulin IgM-class antibodies against M West-Nile virus detection with imūnfermentatīv response 1 study 12.45 0.00 12.45 15.13.12.
Anti-West-Nile (ELISA) immunoglobulin IgG-class antibodies against a G West-Nile virus detection with imūnfermentatīv response 1 study 12.45 0.00 12.45 15.13.13.
West-Nile-RNA (PCR RL) West-Nile virus ribonukleīn acid detection with polymerase chain reaction real time study 63.03 0.00 63.03 15.13.14 1.
Anti-SARS-CoV IgM ELISA) immunoglobulin M antibodies against SARS class CoV by imūnfermentatīv response 1 study 11.73 0.00 11.73 15.13.15.
Anti-SARS-CoV IgG (ELISA) immunoglobulin G antibodies against SARS class CoV by imūnfermentatīv response 1 study 11.73 0.00 11.73 15.13.16.
SARS CoV (PCR RL) – SARS CoV ribonukleīn acid detection with polymerase chain reaction real time study 1st 63.03 0.00 63.03 15.14.
various infectious disease serological and molecular biological diagnostic 15.14.1.
Anti-rubella IgM (ELISA) immunoglobulin M antibodies against rubella class virus detection with imūnfermentatīv response 1 study 8.82 0.00 8.82 15.14.2.
Anti-rubella quantitative IgG (ELISA) immunoglobulin G antibodies against rubella class viral quantification with imūnfermentatīv response 1 study 7.69 0.00 7.69 15.14.3.
Anti-Mycoplasma pneumoniae IgM (ELISA) immunoglobulin M antibodies against Mycoplasma class pneumoniae with imūnfermentatīv response 1 study 7.25 0.00 7.25 15.14.4.
Anti-Mycoplasma pneumoniae IgG (ELISA) immunoglobulin G antibody against Mycoplasma class pneumoniae with imūnfermentatīv response 1 study 7.48 0.00 7.48 15.14.5.
Anti-Chlamydia pneumoniae IgM (ELISA) immunoglobulin M antibodies against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0.00 7.82 15.14.6.
Anti-Chlamydia pneumoniae IgG quantitative (ELISA) immunoglobulin G antibody against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0.00 7.82 15.14.7.
Anti-Toxoplazm (ELISA) of IgM-class antibodies of immunoglobulin M determination of the imūnfermentatīv against Toxoplazm response 1 study 6.51 0.00 6.51 15.14.8.
Anti-Toxoplazm IgG quantitative (ELISA) immunoglobulin G antibodies against Toxoplazm of class identification with imūnfermentatīv response 1 study 5.36 0.00 5.36 15.14.9.
Anti-Toxoplazm IGA (ELISA) immunoglobulin A antibodies against Toxoplazm of class determination with imūnfermentatīv manmad reaction study 1 4.98 0.00 4.98 15.14.10.
Anti-Toxoplazm IgG aviditāt (ELISA) immunoglobulin G antibody against Toxoplazm classes in the aviditāt detection with manmad imūnfermentatīv response 1 study 8.79 0.00 8.79 15.14.11.
Anti-Rubeol (ELISA) of IgM-class antibodies of immunoglobulin M against measles virus detection with imūnfermentatīv response 1 study 9.25 0.00 9.25 15.14.12.
Anti-Rubeol IgG quantitative (ELISA) immunoglobulin G antibody against measles class viral quantification with imūnfermentatīv response 1 study 9.79 0.00 9.79 15.14.13.
measles (Rubeol) virus isolation in tissue culture study 21.84 0.00 21.84 15.14.14 1.
Anti-parvovīrus-B19 IgM (ELISA) immunoglobulin M antibodies against parvovīrus of the class with imūnfermentatīv B19 reaction 1 study 7.60 0.00 7.60 15.14.15.
Parvovīrus B19 IgG Anti-a quantitative (ELISA) immunoglobulin G antibodies against parvovīrus of class determination with B19 immune enzymatic reaction study 7.92 0.00 7.92 15.14.16 1.
papilloma virus (low and high risk of oncogenes) determination by hybridisation 1 study 40.78 0.00 40.78 15.14.17.
Anti-Diphteri (ELISA) of Toxoid IgG immunoglobulin G antibody-class against the Toxoid imūnfermentatīv Diphteri by reaction 1 study 7.07 0.00 7.07 15.14.18.
Anti-IgM Mump (ELISA) immunoglobulin M antibodies against mumps class virus detection with imūnfermentatīv response 1 8.42 0.00 8.42 15.14.19 study.
Anti-IgG by Mump (ELISA) immunoglobulin G antibody-class against mumps virus detection with imūnfermentatīv response 1 study 7.83 0.00 7.83 15.14.20.
papilloma virus (PCR) (low and high risk of oncogenes) identification with polymerase chain reaction study 15.88 0.00 15.88 15.15 1.
bacteriological studies 15.15.1.
bacteriological analysis 15.15.1.1.
blood – with the conventional method (negative) 1 study 10.06 0.00 10.06 15.15.1.2.
blood-with automatic system (negative) 1 study 11.22 0.00 11.22 15.15.1.3.
blood – with the conventional method (positive) 1 study 14.62 0.00 14.62 15.15.1.4.
blood-with automatic system (positive) 1 study 16.42 0.00 16.42 15.15.1.5.
the lumbar punktāt (negative) 1 study 9.48 0.00 9.48 15.15.1.6.
the lumbar punktāt, without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 19.35 0.00 19.35 15.15.1.7.
the punktāt – with a lumbar isseri meningitidis serological tipēšan of (positive) 1 study 18.13 0.00 18.13 15.15.1.8.
plating of the neck – Not the isseri meningitidis (negative) 1 study 5.26 0.00 5.26 15.15.1.9.
plating of the neck – without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 10.94 0.00 10.94 15.15.1.10.
plating of the neck – with the serological detection of n. meningitidis tipēšan isseri (positive) 1 study 16.61 0.00 16.61 15.15.1.11.
urine (negative) 1 study 7.57 0.00 7.57 15.15.1.12.
urine (positive) 1 study 13.55 0.00 13.55 15.15.1.13.
bile (negative) 1 study 7.55 0.00 7.55 15.15.1.14.
bile (positive) 1 study 14.62 0.00 14.62 15.15.1.15.
pus, discharge, punktāt, rinse waters (negative) 1 study 11.89 0.00 11.89 15.15.1.16.
pus, discharge, punktāt, rinse waters (positive) 1 study 15.40 0.00 15.40 15.15.1.17.
sputum (negative) 1 study 6.01 0.00 6.01 15.15.1.18.
sputum (positive) 1 study 16.39 0.00 16.39 15.15.1.19.
plating of the neck – beta haemolytic streptococci (negative) 1 study 8.58 0.00 8.58 15.15.1.20.
plating of the neck – beta haemolytic streptococci (positive) 1 study 10.93 0.00 10.93 15.15.1.21.
plating on different materials – Staphylococcus aureus (negative) 1 study 4.44 0.00 4.44 15.15.1.22.
plating on different materials – the woven Staphyl aureus (positive) 1 study 5.43 0.00 5.43 15.15.1.23.
the culture of the throat and nose, Corynebacterium diphtheriae the – (negative) 1 study 9.64 0.00 9.64 15.15.1.24.
the culture of the throat and nose, Corynebacterium diphtheriae-(positive) 1 study 14.28 0.00 14.28 15.15.1.25.
the culture of the throat and nose, Corynebacterium diphtheriae, the unified system (positive) 1 study 14.21 0.00 14.21 15.15.1.26.
stools – Shigella, salmonella (negative) 1 study 6.32 0.00 6.32 15.15.1.27.
stools – Shigella, salmonella, with the unified system (positive identification to serotype) 1 study 12.18 0.00 12.18 15.15.1.28.
-selection of stools Escherichia (negative) 1 study 7.20 0.00 7.20 15.15.1.29.
-selection of stools Escherichia (positive) 1 study 9.57 0.00 9.57 15.15.1.30.
stools-Escherichia coli 0157 (negative) 1 study 6.10 0.00

6.10 15.15.1.31.
stools-Escherichia coli 0157 (positive) 1 study 11.89 0.00 11.89 15.15.1.32.
different materials-enterobacteriaceae (negative) 1 study 6.91 0.00 6.91 15.15.1.33.
different materials-enterobacteriaceae (positive) 1 study 8.60 0.00 8.60 15.15.1.34.
materials (faeces, urine from the neck) – the genus Yersinia bacteria (negative) 1 study 6.14 0.00 6.14 15.15.1.35.
materials (faeces, urine from the neck)-Yersinia genus bacteria, with the conventional method (positive) 1 study 14.66 0.00 14.66 15.15.1.36.
materials (faeces, urine from the neck)-Yersinia genus bacteria – identification with a unified system (positive) 1 study 9.56 0.00 9.56 15.15.1.37.
plating of different materials to the genus Candida fungi (negative) 1 study 4.07 0.00 4.07 15.15.1.38.
plating from the neck to the genus Candida fungi (positive) study 1 7.64 0.00 7.64 15.15.1.39.
materials (faeces, urine, the lumbar punktāt, blood)-bacteria of the genus Campylobacter (negative) 1 study 6.67 0.00 6.67 15.15.1.40.
materials (faeces, urine, the lumbar punktāt, blood), Campylobacter bacteria in the genus with species identification of up-with the unified system (positive) 1 study 21.28 0.00 21.28 15.15.1.41.
anaerobic micro-organisms (negative) 1 study 11.71 0.00 11.71 15.15.1.42.
anaerobic micro-organisms: the identification with the unified system (positive) 1 study 20.72 0.00 20.72 15.15.1.43.
Vibrio cholerae stools – (negative) 1 study 6.44 0.00 6.44 15.15.1.44.
Vibrio cholerae stools – (positive) 1 study 8.54 0.00 8.54 15.15.1.45.
the antibiotic sensitivity detection of micro-organisms with the unified system 1 study 8.19 0.00 8.19 15.15.1.46.
Botulism-bioprov 1 the examination 17.03 0.00 17.03 15.15.1.47.
plating on Clostridium botulinum (negative) 1 study 11.32 0.00 11.32 15.15.1.48.
plating on Clostridium botulinum (positive) 1 study 20.72 0.00 20.72 15.15.1.49.
distributed micro-organisms antibiotic sensitivity determination by disk method 1 study 6.83 0.00 6.83 15.15.1.50.
the culture of the different materials – MRSA Methicillin S. aureus (negative) study 15.15.1.51 5.45 0.00 5.45 1.
the culture of the different materials – MRSA Methicillin S. aureus (positive) 1 study 8.17 0.00 8.17 15.15.1.52.
in s. aureus Methicillin Mec Gene Discovery (MRSA) by polymerase chain reaction real time study 1st 44.63 0.00 44.63 15.15.1.53.
stools – Shigella, salmonella, with unified method (positive identification to serotype) 1 study 10.21 0.00 10.21 15.15.1.54.
plating of different materials on the Candida fungi of the genus with the unified system (positive, negative) 1 study 8.63 0.00 8.63 15.15.1.55.
material (nails, hair, skin) investigation on fungi 1 study 1.26 0.00 1.26 15.15.1.56.
the investigation of bakterioskopisk mikobaktērij with fluorescent method 1 study 2.15 0.00 2.15 15.15.1.57.
material on the culture of micro-organisms of the genus Mycobacterium 1 study 4.03 0.00 4.03 15.15.1.58.
plating TB diagnosis with the BACTEC system 1 study 17.70 0.00 17.70 15.15.2.
15.15.2.1 serological analysis.
agglutination reaction of bacterial infections (such as whooping cough, typhoid fever, tularemia, brucellosis) 1 study 3.81 0.00 3.81 15.15.2.2.
Aspergillus Antigen with lateksaglutinācij (LA) 1 study 7.44 0.00 7.44 15.15.2.3.
Candida Antigen with lateksaglutinācij (LA) 1 study 7.44 0.00 7.44 15.15.2.4.
haemagglutination reaction bacterial infection (salmonellosis, shigellosis, yersiniosis, pseidotuberkuloz) 1 study 4.54 0.00 4.54 15.15.2.5.
Cryptococc of Antigen with lateksaglutinācij (LA) 1 study 10.43 0.00 10.43 15.15.2.6.
Clostridium difficile toxin A discovery 1 study 8.63 0.00 8.63 15.15.2.7.
Group a beta haemolytic Streptococcus in the quick test 1 study 2.97 0.00 2.97 15.15.2.8.
microscopic diagnosis of leprosy 1 study 1.84 0.00 1.84 No 15.16.
environmental studies 15.16.1 objects.
HAVE Ag (ELISA) – viral hepatitis A Antigen with imūnfermentatīv reaction (sanitary examination) 1 study 8.96 0.00 8.96 15.16.2.
involved and the distribution of adenovīrus (sanitary examination) 1 study 33.09 0.00 33.09 15.16.3.
tick-borne encephalitis (TBE) virus Antigen (ELISA) imūnfermentatīv reaction to mite 1 study 10.97 0.00 10.97 15.16.4.
the washings of environmental objects (positive), the study passage 1 6.34 0.00 6.34 15.16.5.
the washings of environmental objects (negative)-1 plating study 4.16 0.00 4.16 15.17.
laboratory studies of other medical institutions study contractual price 0.00 1 contractual price 15.18.
morphological study of liver bioptāt-light microscopy study 1 19.55 0.00 19.55 16.
Image Diagnostics 16.1.
16.1.1. ultrasonoskopisk inquiry
abdominal sonogrāfij (not including the pelvic organs, with vascular measurement) 1 study 10.35 0.00 10.35 16.1.2.
one of the repeated sonogrāfij of organs (one study) study 1 5.90 0.00 5.90 16.1.3.
kidney, urinary tract, prostate sonogrāfij study 1 9.83 0.00 9.83 16.1.4.
a woman's pelvic organs examination 1 sonogrāfij 9.83 0.00 9.83 16.1.5.
mammary sonogrāfij 1 the examination 9.83 0.00 9.83 16.1.6.
Ultrasonic control made puncture 1 study 24.18 0.00 24.18 16.1.7.
thyroid, muscle, tendons, joints and other superficial structures ultrasound placed 1 study 9.32 0.00 9.32 16.1.8.
rectal and intravagināl sonogrāfij in study 1 8.28 0.00 8.28 16.2.
16.2.1. radiographic examination
the thoracic cavity organs 1 study screened 5.28 0.00 5.28 16.2.2.
the thoracic cavity organs review company 1 study 6.21 0.00 6.21 16.2.3.
the thoracic cavity organs company in two planes 1 study 9.32 0.00 9.32 16.2.4.
the thoracic cavity organs one extra company, including esophageal kontrastēšan 1 the examination 6.47 0.00 6.47 16.2.5.
other institutions of the radiograph evaluation one study 1 study 2.07 0.00 2.07 16.2.6.
abdominal examination 1 4.71 0.00 4.71 16.2.7 screened.
abdominal examination 5.90 0.00 5.90 16.2.8 company 1.
Esophageal contrasting investigation (and Gramma screened) study 1 14.18 0.00 14.18 16.2.9.
esophageal, gastric and duodenal kontrastizmeklēšan 1 the examination of 22.44 0.00 22.44 16.2.10.
esophagus, stomach and duodenum to the rectum, small intestine kontrastizmeklēšan the investigation to study the ileocekāl area 1 24.89 0.00 24.89 16.2.11.
colon Arcade 1 study 20.37 0.00 20.37 16.2.12.
irigoskopij 1 the examination 37.90 0.00 37.90 16.2.13.
intravenous urogrāfij 1 the examination 21.97 0.00 21.97 16.2.14.
skull x-ray each part 1 study 4.66 0.00 4.66 16.2.15.
skull x-ray images two planes 1 study 8.28 0.00 8.28 16.2.16.
mandibular x-ray images (biplane) 1 study 5.90 0.00 5.90 16.2.17.
Sinus one radiograph 1 study 5.18 0.00 5.18 16.2.18.
one tooth company 1 study 4.14 0.00 4.14 16.2.19.
the chest bone or part of a single radiograph 1 study 6.21 0.00 6.21 16.2.20.
limb or part of a single radiograph 1 study 10.35 0.00 10.35 16.2.21.
the shoulder bar or pelvic radiograph of part 1 study 6.21 0.00 6.21 16.2.22.
pelvic bone radiograph 1 study report 16.2.23 6.47 0.00 6.47.
one part of the spine radiograph (biplane) 1 study 11.39 0.00 11.39 16.2.24.
a digital x-ray image recording on disc 1 study 1.55 0.00 1.55 16.2.25.
liver puncture Biopsy study 35.01 0.00 35.01 16.2.26 1.
larynx, throat, trachea, esophagus upper one company study 5.54 0.00 5.54 16.2.27 1.
digital print on 24 x 30 cm film study 2.07 0.00 2.07 16.2.28 1.
digital print 35 x 43 cm to movie 1 study 2.07 0.00 2.07 16.2.29.
head and sinus CT without an examination of the kontrastēšan 1 16.2.30 60.00 0.00 60.00.
abdominal CT without kontrastēšan 1 of multi-layer study 70.00 0.00 70.00 16.2.31.
small pelvic CT without kontrastēšan multi-layer 1 study 70.00 0.00 70.00 16.2.32.
pulmonary radiological study with mobile x-ray equipment 1 study 11.08 0.00 11.08 16.2.33.
chest CT without kontrastēšan multi-layer 1 study 65.00 0.00 65.00 16.2.34.
spine CT without kontrastēšan 1 the examination 70.00 0.00 70.00 17.
Functional diagnostics 17.1.
ezofagoskopij 1 the examination 10.97 0.00 10.97 17.2.
gastroskopij or duodenoskopij 1 the examination 30.00 0.00 30.00 17.3.
rektoskopij 1 the examination 7.66 0.00 7.66 17.4.
colon examination to lean angle 1 study 30.64 0.00 30.64 17.5.
total colon examination 1 study 50.00 0.00 50.00 10.9.
duodenāl probing study 9.47 0.00 1

9.47 11.0.
cleansing enema 1 study 4.45 0.00 4.45 11.1.
Pulse frequency and arterial pressure 1 study 0.31 0.00 0.31 11.1.
electrocardiography with 12 leads (note) 1 study 2.02 0.00 2.02 17.10.
electrocardiography with 12 leads (description) 1 study 2.85 0.00 2.85 17.11.
with fewer than 12 lead electrocardiography (notes) 1 study 0.83 0.00 0.83 17.12.
with fewer than 12 lead electrocardiography (description) 1 study 1.19 0.00 1.19 17.13.
During description (compared to at least five the ECG) 1 study 3.88 0.00 3.88 17.14.
electrocardiography (recorded with a portable machine on site) 1 study 4.66 0.00 4.66 17.15.
ehokardiogrāfij M and B mode real-time unit and haemodynamic indicators, dopplerogrāfij and spectral 1 study 26.20 0.00 26.20 17.16.
external breathing fundamentals (VC, and Tiffn with the index) discovery and analysis 1 study 2.47 0.00 2.47 17.17.
gaseous diffusion procedure 1 10.20 0.00 10.20 17.18.
veloergometrij procedure 1 8.41 0.00 8.41 17.19.
spirogāfij procedure 1 4.50 0.00 4.50 17.20.
spirogrāfij with the bronhodilatācij test and pretbaktērij filter 1 procedure 6.00 0.00 6.00 17.21.
kardiopulmonāl-load test procedure 11.11 0.00 11.11 18 1.
The Bronhoskopij 18.1.
with the bronhoskop rigīd bronhoskopij 1 procedure 12.10 0.00 12.10 18.2.
1 procedure fibrobronhoskopij 18.40 0.00 18.40 18.3.
the bonus of the trachea and the bronchial mucosa biopsy procedure 7.10 0.00 7.10 1 18.4.
Supplement for transbronhiāl lung tissue biopsy procedure 1 8.12 0.00 8.12 18.5.
the bonus of videoskopij equipment 1 procedure 6.00 0.00 6.00 18.6.
bonus on bronchial alveolar-lavāž (BALA) 1 procedure 3.43 0.00 3.43 18.7.
foreign body removal from the airway 1 procedure 5.01 0.00 5.01 12.8.
latent tuberculosis infection detection test in vitro procedure 51.00 0.00 51.00 19 1.
Other manipulation and procedures 19.1.
Mantoux 1 procedure 0.80 0.00 0.80 19.2.
The reaction of reading 1 Mantoux procedure 0.40 0.00 0.40 19.3.
skin prick test with 1 allergen 2.21 0.00 2.21 19.4 procedure 1.
skin prick test for each allergen 1 0.80 0.00 0.80 procedure notes.
1. Value added tax does not apply, in accordance with the law "on value added tax" article 6, first paragraph, point 9.1.
2. The service provides patients the infection. "
2. Be declared unenforceable in the Cabinet of 10 January 2006, Regulation No 30 "rules on tuberculosis and lung disease national agencies provide public pay-services price list" (Latvian journal, 2006, no. 11; 2007, nr. 184).
Prime Minister Dombrovskis v. Minister of health b. Rosenthal is the Editorial Note: rules shall enter into force 24 October 2009.